Welcome to our dedicated page for Polomar Health Services SEC filings (Ticker: PMHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Polomar Health Services's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Polomar Health Services's regulatory disclosures and financial reporting.
Polomar Health Services (PMHS) reported a net loss of $1,712,193 for the nine months ended September 30, 2025, on revenue of $16,174, and disclosed substantial doubt about its ability to continue as a going concern. Cash was $38,854 with an accumulated deficit of $4,623,356 and a stockholders’ deficit of $7,766,596. Revenue fell sharply from $37,954 in the prior-year period while operating expenses, mainly general and administrative costs of $1,588,725, remained high. The business is being repositioned from local dermatology compounding to online fulfillment of GLP-1 and men’s health drugs and relies heavily on third-party telehealth platforms. To fund operations, the company entered into multiple related-party promissory notes and issued Series A Convertible Preferred Stock. It also signed a $750,000 guaranteed-payment ForHumanity licensing deal for inhalable drugs and agreed to an Altanine merger under which Altanine holders are expected to own about 80% of the combined company.
Polomar Health Services, Inc. filed a late notice for its Q3 2025 Form 10‑Q, citing unexpected delays in completing financial statements and stating it expects to file within five calendar days.
The company highlighted significant operational changes following its September 30, 2024 reverse recapitalization with Polomar Specialty Pharmacy and a shift from retail to wholesale. For the nine months ended September 30, 2025, revenue was approximately $16,174 versus $37,954 a year earlier, while operating expenses were approximately $1,618,886 versus $632,217. The company reported a net loss of approximately $1,712,194 compared with $622,544 in the prior period, reflecting higher legal, accounting, consulting, interest, and payroll costs.
Polomar Health Services, Inc. announced a First Amendment to its Agreement and Plan of Merger and Reorganization with Altanine Inc., updating the exchange terms for the planned combination. The amendment defines the “Exchange Ratio” as one share of Parent Common Stock for each share of Company Common Stock and five shares of Parent Preferred Stock for each share of Company Preferred Stock, subject to adjustment.
The amendment, dated October 8, 2025, applies to the merger among Polomar Health, its wholly owned subsidiary Polomar Merger Sub, Inc., and Altanine Inc. The company attached the full amendment as Exhibit 2.1 and incorporated it by reference.
Polomar Health Services (PMHS) insider buying disclosed on Form 4. Terrence M. Tierney, President and Director, reported three open-market purchases: 125,000 shares on 06/27/2025, 8,333 shares on 07/15/2025 and 7,695 shares on 08/15/2025, bringing his beneficial ownership to 141,028 shares. Reported aggregate cash amounts are shown for each lot on the form. The Form 4 is signed by the reporting person.
Polomar Health Services, Inc. filed an S-1 describing a recent recapitalization, related-party financings, and material liquidity constraints. The company sold 90,437,591 common shares (about 83% of issued and outstanding) and 500,000 Series A preferred shares to CWR 1, LLC for $350,000. The former CEO and chairman resigned. The filing discloses multiple promissory notes and related-party advances including a Reprise Note with outstanding principal of $716,402.67 and accrued interest of $29,508.91 as of December 31, 2024 (amended and larger balances reported through June 30, 2025), a $150,000 CWR Note II with initial 12% APR and milestone draws, and other notes exchanged for preferred stock.
The company reported no cash equivalents, net loss of $1,341,333 for 2024, accumulated deficit of $2,911,163 as of December 31, 2024 (increased to $3,973,581 as of June 30, 2025), and explicit substantial doubt about its ability to continue as a going concern within one year.